Postoperative Pain and Angiotensin II Receptor Antagonists
Unknown statusPhase 4NCT02513979
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
An angiotensin II type 2 receptor (AT2R) antagonist has been assessed for its efficacy in neuropathic pain with promising results. A considerable number of patients undergoing surgery under general anesthesia are hypertensive and receive drugs to control high blood pressure, including angiotensin II receptor antagonists. These drugs may attenuate the acute and/or chronic postoperative pain or decrease the analgesic requirements after surgery. The aim of the present study is to assess the early postoperative pain and analgesic requirements in patients treated with antagonists of the angiotensin II receptors for at least three months before surgery compared to normotensive patients.
Study details
- Official title
- The Effect of Angiotensin II Receptor Antagonists on Acute and Chronic Postoperative Pain in Patients Treated for Hypertension.
- Conditions
- Interventions
- Drug: Angiotensin type II receptor antagonists
- Sponsor
- University of Athens
- Start date
- 2015-08
- Primary completion
- 2017-10
- Sex
- All
- Age range
- from 35 Years to 79 Years
- Results posted
- No results posted in this snapshot
- Countries
- Greece
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients aged between 35 and 79 years * ASA II or III * BMI ≤ 35 * Elective abdominal surgery Exclusion Criteria:- * Patients on analgesic, antidepressive, or sedative consumption during the last month * Mental impairment * Not speaking fluently Greek language * Refuse to give written informed consent * Diabetics * Patients receiving antihypertensive treatment other than angiotensin type II receptor (AT2R) antagonists
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02513979